Acetic Anhydride → HCID 71272066, compound
Reaction equation
[CH3:1][C:2]1[C:17]([CH2:18][C:19]2[CH:24]=[CH:23][CH:22]=[C:21]([C:25]([F:28])([F:27])[F:26])[C:20]=2[CH3:29])=[C:5]2[N:6]=[C:7]([N:11]3[CH2:16][CH2:15][O:14][CH2:13][CH2:12]3)[CH:8]=[C:9]([NH2:10])[N:4]2[N:3]=1.[C:30](OC(=O)C)(=[O:32])[CH3:31]>CN(C=O)C>[CH3:1][C:2]1[C:17]([CH2:18][C:19]2[CH:24]=[CH:23][CH:22]=[C:21]([C:25]([F:28])([F:26])[F:27])[C:20]=2[CH3:29])=[C:5]2[N:6]=[C:7]([N:11]3[CH2:16][CH2:15][O:14][CH2:13][CH2:12]3)[CH:8]=[C:9]([NH:10][C:30](=[O:32])[CH3:31])[N:4]2[N:3]=1Participants
4
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
To a solution of 2-methyl-3-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-5-(4-morpholinyl)pyrazolo[1,5-a]pyrimidin-7-amine (120 mg, 0.3 mmol), prepared as described in Example 17, in DMF (1 mL) was added acetic anhydride (30 mg, 0.3 mmol). Reaction mixture was stirred overnight. Reaction mixture was concentrated to dryness and dissolved with DMSO (1 mL). The crude product was purified by reversed phase HPLC to provide the titled compound (15 mg, 11%); LC/MS: MS (ES+) m/e 448 (MH+); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.25 (s, 3H) 2.30 (s, 3H) 2.44-2.48 (m, 3H) 3.38-3.50 (m, 4H) 3.61-3.70 (m, 4H) 3.95 (s, 2H) 7.20 (s, 1H) 7.28 (d, J=7.83 Hz, 1H) 7.37 (d, J=7.07 Hz, 1H) 7.51 (d, J=7.83 Hz, 1H) 10.60 (s, 1H).
Workup
- customReaction mixture
- customReaction mixture
- concentrationwas concentrated to dryness
- dissolutiondissolved with DMSO (1 mL)
- customThe crude product was purified by reversed phase HPLC
Sources & evidence
- ORD record
- ord-50e716d197924c8ea08b87eb99b70cbb
- Source dataset
- uspto-grants-2015_08
- Patent number
- US09096605B2
Reaction notes
Loading…